All results

2 results for phase 2 multi center double blind randomized dose ranging placebo controlled study

• IMPALA-2

  160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…

  Ages

  18 Years - N/A

  Sexes

  All

• Vasomune AV001-004

  A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring…

  Ages

  18 Years - N/A

  Sexes

  All